[go: up one dir, main page]

WO2015145388A3 - Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt - Google Patents

Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt Download PDF

Info

Publication number
WO2015145388A3
WO2015145388A3 PCT/IB2015/052245 IB2015052245W WO2015145388A3 WO 2015145388 A3 WO2015145388 A3 WO 2015145388A3 IB 2015052245 W IB2015052245 W IB 2015052245W WO 2015145388 A3 WO2015145388 A3 WO 2015145388A3
Authority
WO
WIPO (PCT)
Prior art keywords
wnt pathway
methods
colorectal cancers
treating colorectal
pathway mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/052245
Other languages
English (en)
Other versions
WO2015145388A2 (fr
Inventor
Linda BAGDASARIAN
Feng Cong
Savina JAEGER
Margaret Elise CLAUGHLIN
Ronald Meyer
Andrea MYERS
Michael Ross PALMER
Youzhen Wang
Stephen David WOOLFENDEN
Ana VIVANCOS
Héctor PALMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2015145388A2 publication Critical patent/WO2015145388A2/fr
Publication of WO2015145388A3 publication Critical patent/WO2015145388A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé de traitement de patients souffrant d'un cancer colorectal, plus spécifiquement un mutant de BRAF V600E ou BRAF type sauvage, à l'exception de KRAS de type sauvage et d'un cancer colorectal à instabilité microsatellitaire à l'aide d'un inhibiteur de la voie Wnt ou d'une combinaison comprenant un inhibiteur de la voie Wnt et un inhibiteur de BRAF et/ou inhibiteur d'EGFR. L'invention concerne en outre des formulations pharmaceutiques, des utilisations, des procédés, des combinaisons, et des modes de réalisation associés.
PCT/IB2015/052245 2014-03-27 2015-03-26 Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt Ceased WO2015145388A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461971162P 2014-03-27 2014-03-27
US61/971,162 2014-03-27
US201562119939P 2015-02-24 2015-02-24
US62/119,939 2015-02-24

Publications (2)

Publication Number Publication Date
WO2015145388A2 WO2015145388A2 (fr) 2015-10-01
WO2015145388A3 true WO2015145388A3 (fr) 2016-01-28

Family

ID=52815064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/052245 Ceased WO2015145388A2 (fr) 2014-03-27 2015-03-26 Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt

Country Status (2)

Country Link
TW (1) TW201620548A (fr)
WO (1) WO2015145388A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109415342A (zh) * 2016-06-22 2019-03-01 诺华股份有限公司 用于治疗纤维化的wnt抑制剂
EP3559264A4 (fr) * 2016-12-21 2020-08-12 Agency for Science, Technology and Research Kit d'identification d'une affection maligne et ses utilisations
WO2019245460A1 (fr) * 2018-06-21 2019-12-26 National University Of Singapore Stratification de patients cancéreux hébergeant des mutations oncogènes dans l'ubiquitine ligase e3 rnf43
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120059021A1 (en) * 2008-11-11 2012-03-08 University Of Washington Compositions and methods for treating cancer and methods for predicting a response to such treatments
WO2013086260A2 (fr) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Thérapie d'association pour le traitement du cancer
WO2013130364A1 (fr) * 2012-02-28 2013-09-06 Novartis Ag Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43
WO2014025688A1 (fr) * 2012-08-07 2014-02-13 Novartis Ag Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
WO1997049688A1 (fr) 1996-06-24 1997-12-31 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
CA2265630A1 (fr) 1996-09-13 1998-03-19 Gerald Mcmahon Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120059021A1 (en) * 2008-11-11 2012-03-08 University Of Washington Compositions and methods for treating cancer and methods for predicting a response to such treatments
WO2013086260A2 (fr) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Thérapie d'association pour le traitement du cancer
WO2013130364A1 (fr) * 2012-02-28 2013-09-06 Novartis Ag Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43
WO2014025688A1 (fr) * 2012-08-07 2014-02-13 Novartis Ag Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GIORDANO CAPONIGRO: "Abstract 2337: Efficacy of the RAF/PI3K[alpha]/anti-EGFR triple combination LGX818 + BYL719 + cetuximab in BRAFV600E colorectal tumor models.", 6 April 2013 (2013-04-06), XP055200917, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/73/8_Supplement/2337.short> [retrieved on 20150708] *
ISAAC SCHAMALE: "Wnt Signaling Pathway Inhibition Enhances Efficacy of Cetuximab", OTOLARYNGOLOGY -- HEAD AND NECK SURGERY, 1 September 2013 (2013-09-01), pages 81 - 82, XP055219423, Retrieved from the Internet <URL:http://oto.sagepub.com/content/149/2_suppl/P81.3> [retrieved on 20151008] *
J. LIU ET AL: "Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 50, 25 November 2013 (2013-11-25), pages 20224 - 20229, XP055121007, ISSN: 0027-8424, DOI: 10.1073/pnas.1314239110 *
K. TAKADA ET AL: "Targeted Disruption of the BCL9/ -Catenin Complex Inhibits Oncogenic Wnt Signaling", SCIENCE TRANSLATIONAL MEDICINE, vol. 4, no. 148, 22 August 2012 (2012-08-22), pages 148ra117 - 148ra117, XP055150823, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.3003808 *
LUCA MOLOGNI ET AL: "Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells", PLOS ONE, vol. 7, no. 12, 5 December 2012 (2012-12-05), pages e51449, XP055200401, DOI: 10.1371/journal.pone.0051449 *
M. CASAS-SELVES ET AL: "Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition", CANCER RESEARCH, vol. 72, no. 16, 15 August 2012 (2012-08-15), US, pages 4154 - 4164, XP055218639, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-11-2848 *
T. L. BIECHELE ET AL: "Wnt/ -Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma", SCIENCE SIGNALING, vol. 5, no. 206, 10 January 2012 (2012-01-10), US, pages ra3 - ra3, XP055218840, ISSN: 1945-0877, DOI: 10.1126/scisignal.2002274 *
X. JIANG ET AL: "Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 31, 11 July 2013 (2013-07-11), pages 12649 - 12654, XP055200712, ISSN: 0027-8424, DOI: 10.1073/pnas.1307218110 *

Also Published As

Publication number Publication date
WO2015145388A2 (fr) 2015-10-01
TW201620548A (zh) 2016-06-16

Similar Documents

Publication Publication Date Title
MY196830A (en) Kras g12c inhibitors and methods of using the same
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
PH12016502453A1 (en) Heteroaryl compounds for kinase inhibition
EA201992781A1 (ru) Ингибиторы g12c kras и способы их применения
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
WO2014116833A3 (fr) Compositions et procédés de détection de néoplasie
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP4327809A3 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3258966A4 (fr) Méthodes, compositions et trousses pour le traitement du cancer
WO2014164704A3 (fr) Composés et compositions utilisables en vue du traitement du cancer
HK1251567A1 (zh) 用於激酶抑制的杂芳基化合物
WO2014138364A3 (fr) Méthodes de traitement et de prévention de la résistance à un médicament d&#39;un cancer
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
MX2016014436A (es) Derivados de heterociclil-butanamida.
EP2996721A4 (fr) Méthodes et compositions pour pronostiquer, diagnostiquer et traiter un cancer exprimant adam8
EP3292218A4 (fr) Compositions et méthodes pour la surveillance, le diagnostic, le pronostic, la détection et le traitement du cancer
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
WO2018094106A3 (fr) Antagonistes allostériques de gprc6a et leur utilisation dans l&#39;atténuation de protéinopathies
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
WO2015145388A3 (fr) Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
EP4218789A3 (fr) Compositions pour le nettoyage du colon et le traitement de troubles gastrointestinaux
HK1249756A1 (zh) 用於治疗疾病的稠合双环化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15714960

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15714960

Country of ref document: EP

Kind code of ref document: A2